2010 Fiscal Year Final Research Report

Development of ultrasound based molecular imaging in an attempt to predict early response of antiangiogenic therapy

Research Project

Project/Area Number	21800055
Research Category	Grant-in-Aid for Research Activity Start-up
Allocation Type	Single-year Grants
Research Field	Medical systems
Research Institution	Tokyo Medical University
Principal Investigator	SUGIMOTO Katsutoshi Tokyo Medical University, 医学部, 助教 (20385032)
Project Period (FY)	2009 – 2010
Keywords	造影超音波 / 分子標的がん治療薬 / 肝細胞癌 / 治療効果判定 / 分子標的バブル / ソナゾイド
Research Abstract	We conducted a study to determine the utility of contrast-enhanced ultrasonography (CE US) as a prognostic tool for advanced hepatocellular carcinoma (HCC) patients receiving sorafenib and to identify CE US parameters that correlate with early treatment response. As a results, CE US can be used to quantify dynamic changes in tumor vascularity as early as several days after sorafenib administration in patients with HCC. These early changes in tumor perfusion may be predictive of tumor response at 1 month, and they may be potential surrogate measures of the effectiveness of antiangiogenic therapy in patients with HCC.